PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 2 | 2 | 105-109
Article title

Postępowanie w zakrzepie żyły środkowej siatkówki z obrzękiem plamki

Content
Title variants
EN
Treatment of retinal vein occlusion with macular edema
Languages of publication
PL
Abstracts
PL
Zakrzep żyły siatkówki (RVO, retinal vein occlusion) i wynikające z niego powikłania stanowią obok makulopatii cukrzycowej najczęstszą naczyniową przyczynę upośledzenia widzenia na świecie. Postępowanie w RVO obejmuje identyfikację i leczenie czynników ryzyka oraz rozpoznanie i leczenie zagrażających upośledzeniu wzroku powikłań. Istotną rolę w leczeniu obrzęku plamki w RVO odgrywają iniekcje anty-VEGF. Fotokoagulacja może być skuteczna jedynie w leczeniu zakrzepu gałęzi żyły środkowej siatkówki.
EN
Retinal vein occlusion (RVO) and the resulting complications of diabetic maculopathy are the next most common vascular cause of impaired vision in the world. Management of RVO include identification and treatment of risk factors, diagnosis and treatment of vision impairment threatening complications. An important role in the treatment of macular edema in RVO play injections of anti-VEGF.
Discipline
Publisher
Journal
Year
Volume
2
Issue
2
Pages
105-109
Physical description
Contributors
  • Oddział Okulistyki, Szpital Czerniakowski w Warszawie
  • Oddział Okulistyki, Szpital Czerniakowski w Warszawie
References
  • 1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-319.
  • 2. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-1247.
  • 3. Mirshahi A, Feltgen N, Hansen LL, et al. Retinal vascular occlusions: an interdisciplinary challenge. Dtsch Arztebl Int 2008; 105: 474-479.
  • 4. Risk Factors for Central Retinal Vein Occlusion. The Eye Disorders Case-Control Study Group. Arch Ophthalmol 1996; 114: 545- -554.
  • 5. Natural history and clinical management of central retinal vein occlusion. Central Retinal Vein Occlusion Study Group. Arch Ophthalmol 1997; 115: 486-491.
  • 6. NICE Interventional Procedure Guidance IPG334. Arteriovenous crossing sheathotomy for branch retinal vein occlusion [http://guidance.nice.org.uk/IPG334. issued 24 March 2010. Accessed 22 Sep 2010].
  • 7. Brown DM, Campochiaro PA, Singh RP, et al.; for CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: 6-month primary endpoint results of a phase III study. Ophthalmology 2010; 117: 1124-1133.
  • 8. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119(4): 802-809.
  • 9. Brown DM, Heier JS, Clark W; Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study Secondary to Central Retinal Vein Occlusion. Am J Ophthalmol 2013; 155: 429-437.
  • 10. Haller JA, Bandello F, Belfort R Jr, et al.; OZURDEX GENEVA Study Group. Randomised, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.e3.
  • 11. Shilling JS, Jones CA. Retinal branch vein occlusion: A study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol 1984; 68: 196-198.
  • 12. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Retinal Vein Occlusion Study Group N report. Ophthalmology 1995; 102: 1434-1444.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-a78f31db-35a9-4591-9e02-108cd877326f
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.